Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL 60637, USA.
Cancer Biomark. 2013;13(3):161-9. doi: 10.3233/CBM-130347.
Adrenergic signaling results from the effects of the catecholamines epinephrine and norepinephrine, on alpha- and beta-adrenergic receptors. In breast cancer, preclinical models suggest that this pathway may influence breast cancer progression through 1) increasing tumor cell survival after exposure to chemotherapeutic agents; 2) increasing breast cancer cell proliferation; and 3) altering the tumor microenvironment in angiogenesis and the inflammatory response. Epidemiologic data have suggested a correlation between drugs that indirectly affect the adrenergic pathway and breast cancer incidence. In addition, there is retrospective evidence suggesting that the use of β-adrenergic blockers in early stage breast cancer patients correlates with an increased time to recurrence. Here we review evidence from both pre-clinical models and epidemiological studies that have examined the question of whether adrenergic signaling may modify breast cancer biology.
肾上腺素能信号来自儿茶酚胺肾上腺素和去甲肾上腺素对α-和β-肾上腺素能受体的影响。在乳腺癌中，临床前模型表明，该途径可能通过以下方式影响乳腺癌的进展：1）增加肿瘤细胞在接触化疗药物后的存活；2）增加乳腺癌细胞增殖；3）改变血管生成和炎症反应中的肿瘤微环境。流行病学数据表明，间接影响肾上腺素能途径的药物与乳腺癌发病率之间存在相关性。此外，还有回顾性证据表明，早期乳腺癌患者使用β-肾上腺素能阻滞剂与复发时间延长相关。在这里，我们回顾了来自临床前模型和流行病学研究的证据，这些研究探讨了肾上腺素能信号是否可能改变乳腺癌生物学的问题。
